First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial - Summary - MDSpire

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • By

  • Peter Schmid

  • Seock-Ah Im

  • Zbigniew Nowecki

  • Piotr J. Wysocki

  • Jacek Jassem

  • Kyung Hae Jung

  • Simon Lord

  • Jon Armstrong

  • Ross Stewart

  • Petra Vuković

  • Neelima Denduluri

  • Yeon Hee Park

  • June 8, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of durvalumab in combination with trastuzumab deruxtecan (T-DXd) for women with locally advanced unresectable or metastatic hormone-receptor-negative HER2-low breast cancer.

Key Findings:
  • Confirmed objective response rate (ORR) was 62.1% (36/58), with 1 complete response and 35 partial responses.
  • Median age of participants was 54 years; 79.3% had PD-L1-negative tumor status.
  • The most common reason for treatment discontinuation was disease progression.
Interpretation:

Limitations:
  • The study did not meet the protocol-specified objective for response rate.
  • High rate of treatment discontinuation due to disease progression.
Conclusion:

Original Source(s)

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • by Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J. Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

  • June 8, 2026

Related Content

A multi-task deep learning framework for simultaneous prediction of microsatellite instability and tumor mutational burden in gastric cancer from histopathological images

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology